Shilpa Biologicals, a wholly owned subsidiary of Shilpa Medicare has filed its first Drug Master File of recombinant Human Albumin 20% with USFDA.
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process which is completely-Environment friendly, Consistent High-Quality product, Scalable to massive scales and is cost competitive.
Recombinant Human Albumin 20% targets to fulfil growing demand of human serum albumin to deliver current and growing market demand.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
